2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk
2014
Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies
Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecologic Oncology 2014, 135: 163-171. PMID: 25072931, PMCID: PMC4404750, DOI: 10.1016/j.ygyno.2014.07.095.Peer-Reviewed Original ResearchConceptsDisease-specific mortalityIncident endometrial cancerEndometrial cancerDiabetes mellitusCohort studyRelative riskStatistical heterogeneityIncidence of ECSummary incidence rate ratioEC-specific mortalityOriginal cohort studyNon-diabetic womenSummary relative riskCochrane's Q statisticIncidence rate ratiosRisk of biasStandardized mortality ratioSignificant statistical heterogeneitySmall-study effectsChi-square testDM statusGynecological oncologyIndependent associationMortality ratioEgger's test